SecBot SecBot
SECBOTREPLAY Home › Report › AZN

AZN · AstraZeneca completed its previously announced exclusive global license…

ASTRAZENECA PLC · 6-K filed Sep 1, 2026 at 07:10 ET

At the news

NEUTRALIMPACT 5/10

6-K filed Sep 1, 2026 at 07:10 ET

AstraZeneca completed its previously announced exclusive global license agreement with Dizal Pharmaceutical for Zegfrovy (sunvozertinib), an oral EGFR inhibitor for NSCLC with exon 20 insertion mutations. AstraZeneca paid $600M upfront with up to $900M in milestones plus tiered royalties, gaining worldwide rights to a drug already approved in the US and China for 2nd-line treatment and under FDA review for 1st-line use. The deal strengthens AstraZeneca's lung cancer portfolio but the $600M upfront and potential $1.5B total consideration represent a material cash outlay with no near-term revenue contribution, and the company stated it does not impact 2026 financial guidance.

  • AstraZeneca completed an exclusive global license agreement with Dizal Pharmaceutical for Zegfrovy (sunvozertinib), an oral EGFR inhibitor for NSCLC.
  • AstraZeneca made a $600M upfront payment to Dizal, with up to $900M in additional milestone payments and tiered royalties on global sales.
  • Zegfrovy is already approved in the US and China for 2nd-line treatment of NSCLC with EGFR exon 20 insertion mutations.
  • A supplemental NDA for 1st-line use has been accepted by the FDA, supported by positive Phase III WU-KONG28 trial data.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access